Aranesp (darbepoetin alfa), the new longer-acting erythropoietin analog for anemia
November 2001
You'll see patients getting Aranesp (darbepoetin alfa), the new longer-acting erythropoietin analog for anemia.
Aranesp is approved for anemia associated with chronic renal failure...including patients on dialysis, and those not on dialysis.
It's also being studied for anemia due to cancer chemotherapy.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote